SCOPE Analytic Treatment Interruption Protocol
ConditionHIV/AIDS
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of California, San Francisco
About this trial
The goal of this study is to understand the interaction between HIV and the host at the earliest stages when HIV medications are paused. Volunteers with HIV will interrupt antiretroviral therapy (ART) and then have intensive studies preformed two to three times per week. Most will resume therapy within three weeks, even if the virus does not rebound during this time.
Eligibility criteria
Qualifiers
Willing and able to provide written informed consent
Age >= 18
Documented HIV infection
Antiretroviral therapy for at least 12 months
Disqualifiers
Pregnant or plans to become pregnant during the course of the study
Active hepatitis B, defined as (1) positive sAg or (2) positive cAb with negative sAb and positive HBV DNA
Active hepatitis C, defined as positive Hep C Ab with positive HCV RNA
Use of a non-nucleoside reverse transcriptase inhibitor and unable to switch regimen
Trial design
Treatments tested in this trial
- Treatment Interruption Arm
Treatment groups
40 Participants
are divided into 1 treatment groupSponsors and collaborators
University of California, San Francisco
Lead sponsor
Chan Zuckerberg Biohub
Collaborator
Source ClinicalTrials.gov